Tuesday, October 27, 2020
Machine learning and artificial intelligence have emerged as innovative ways to maximize the data that can be generated by liver biopsy samples. The goal of this session was to review the state of the field, and dive into the logistical, technical, and regulatory hurdles that must be addressed for these technologies to go from being used in exploratory fashion to being accepted for use in clinical trials.